Jupiter Neurosciences Locks In Exclusive U.S. Rights to ALA-002 in Deal Worth Up to $100M
JUNS sits 36% above its 52-week low of $0.159 on light trading volume (0.1× avg).
Summary
Jupiter Neurosciences has signed a definitive license agreement with PharmAla Biotech for exclusive U.S. rights to ALA-002, a patented MDMA-based therapeutic candidate. The deal includes a $3.3M upfront payment (part cash, part stock) and up to $96.7M in milestone payments tied to clinical and commercial progress, plus a 3% royalty on future U.S. sales. This transforms Jupiter's pipeline, adding a second clinical-stage CNS asset alongside JOTROL for Parkinson's. The agreement follows a term sheet announced in May and provides concrete financial terms, signaling commitment from both parties. For a micro-cap company with a market cap under $8M, securing a potentially transformative asset with modest upfront cash is a notable strategic move, though significant clinical and financing risks remain.
At the time of this announcement, JUNS was trading at $0.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.16 to $1.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.